Novartis to acquire SanReno's product pipeline and capabilities, including the exclusive rights for Greater China and Singapore

诺华将收购SanReno的产品线和能力，包括大中华区和新加坡的专有权

Transaction reflects the Novartis commitment to the Chinese market and complements existing pipeline in renal diseases.

该交易反映了诺华对中国市场的承诺，并补充了现有的肾脏疾病管道。

SHANGHAI, Jan. 5, 2024 /PRNewswire/ -- SanReno Therapeutics, a clinical-stage company specializing in the discovery, development, and commercialization of innovative therapies for kidney diseases, today announces its acquisition by Novartis, a global medicines company.  Following the acquisition's closure, SanReno becomes an indirect, wholly-owned subsidiary of Novartis.

上海，2024年1月5日/PRNewswire/--SanReno Therapeutics是一家临床阶段公司，专门从事肾脏疾病创新疗法的发现，开发和商业化，今天宣布其被全球制药公司诺华收购。收购结束后，SanReno成为诺华的间接全资子公司。

The founding investors of SanReno, including Pivotal bioVenture Partners China, Frazier Life Sciences, Samsara BioCapital, and Versant Ventures, have sold their equity securities in SanReno..

SanReno的创始投资者，包括关键的bioVenture Partners China、Frazier Life Sciences、Samsara BioCapital和Versant Ventures，已经出售了他们在SanReno的股权。。

Established in late 2021 as a joint venture between the investor consortium and Chinook Therapeutics (now part of Novartis), SanReno holds exclusive rights in Greater China and Singapore for two late-stage assets targeting Immunoglobulin A Nephropathy (IgAN): atrasentan and zigakibart. Atrasentan, an oral endothelin A receptor antagonist (ERA), is presently undergoing Phase 3 development for IgAN.

SanReno成立于2021年末，是投资财团和Chinook Therapeutics（现为诺华的一部分）的合资企业，在大中华区和新加坡拥有针对免疫球蛋白a肾病（IgAN）的两项晚期资产的专有权：atrasentan和zigakibart。Atrasentan是一种口服内皮素A受体拮抗剂（ERA），目前正在进行IgAN的3期开发。

It demonstrated clinically meaningful and highly statistically significant proteinuria reduction at the 36-weeks interim analysis, successfully meeting the primary endpoint of its Phase 3 study. Zigakibart (BION-1301), a subcutaneously administered monoclonal antibody targeting APRIL (A Proliferation Inducing Ligand), obtained approval from China CDE for entry into the Phase 3 study in October 2023..

在36周的中期分析中，它证明了临床上有意义且具有高度统计学意义的蛋白尿减少，成功地达到了其3期研究的主要终点。Zigakibart（BION-1301）是一种皮下注射的针对APRIL（一种增殖诱导配体）的单克隆抗体，于2023年10月获得中国CDE的批准，可进入3期研究。。

Completed within the first two years of SanReno's formation, this acquisition is one of the few transactions where a Chinese biotech company has been acquired by a multinational pharmaceutical company. The transaction underscores China's substantial market potential within the global renal market and is in strategic alignment with the Novartis commitment to pioneering innovative therapies for kidney diseases..

此次收购在SanReno成立的头两年内完成，是中国生物技术公司被跨国制药公司收购的少数交易之一。该交易突显了中国在全球肾脏市场的巨大市场潜力，并与诺华开创肾脏疾病创新疗法的承诺保持战略一致。。

'The acquisition of SanReno by Novartis is a testament to the unwavering dedication and relentless innovation of the SanReno team. It validates our commitment to pushing the boundaries in kidney disease therapeutics,' said Haoyu Huang, Chief Executive Officer of SanReno Therapeutics. 'We are thrilled to join forces with Novartis, a global pharmaceutical leader, in our shared mission to bring forth potentially transformative medicines for patients battling kidney diseases in China and beyond.

“诺华收购SanReno证明了SanReno团队坚定不移的奉献精神和不懈的创新。SanReno therapeutics首席执行官黄浩宇（Haoyu Huang）说，这证明了我们致力于推动肾脏疾病治疗领域的突破我们很高兴能与全球制药领导者诺华（Novartis）携手合作，共同致力于为中国及其他地区的肾脏疾病患者提供具有潜在变革性的药物。

Today marks an exciting new chapter in our journey to making a meaningful impact in the field of renal health.'.

今天标志着我们在肾脏健康领域产生有意义影响的旅程中翻开了令人兴奋的新篇章。”。

About Atrasentan and Zigakibart

关于Atrasentan和Zigakibart

At the core of our innovative portfolio is a targeted clinical approach to Immunoglobulin A Nephropathy (IgAN). Our flagship asset, Atrasentan, an oral endothelin A receptor antagonist (ERA), is advancing through Phase 3 development for IgAN and achieved the primary endpoint in proteinuria reduction.

我们创新投资组合的核心是针对免疫球蛋白a肾病（IgAN）的靶向临床方法。我们的旗舰资产Atrasentan是一种口服内皮素A受体拮抗剂（ERA），正在通过IgAN的3期开发，并实现了蛋白尿减少的主要终点。

In addition, Zigakibart (BION-1301), our subcutaneously administered anti-APRIL (A Proliferation Inducing Ligand) monoclonal antibody, received regulatory approval from China CDE to commence Phase 3 studies..

此外，我们皮下注射的抗APRIL（一种增殖诱导配体）单克隆抗体Zigakibart（BION-1301）获得了中国CDE的监管批准，开始了3期研究。。

About SanReno Therapeutics

关于SanReno Therapeutics

SanReno Therapeutics is a leading clinical-stage enterprise specializing in the strategic development, exploration, and commercialization of revolutionary therapies tailored for kidney diseases. Our key assets focus on treating Immunoglobulin A Nephropathy (IgAN). Atrasentan, an oral endothelian A receptor antagonist (ERA), has reached Phase 3 with success in reducing proteinuria.

SanReno Therapeutics是一家领先的临床阶段企业，专门从事针对肾脏疾病的革命性疗法的战略开发，探索和商业化。我们的关键资产集中于治疗免疫球蛋白A肾病（IgAN）。Atrasentan是一种口服内皮素A受体拮抗剂（ERA），已达到3期，并成功减少蛋白尿。

Zigakibart, our anti-APRIL (A Proliferation Inducing Ligand) antibody, received regulatory approval for Phase 3 studies. SanReno is dedicated to delivering transformative medicines for critical unmet needs in kidney disease therapeutics, driving advancements and setting new benchmarks in the field..

我们的抗APRIL（一种增殖诱导配体）抗体Zigakibart获得了3期研究的监管批准。SanReno致力于为肾脏疾病治疗中尚未满足的关键需求提供变革性药物，推动该领域的进步并设定新的基准。。

SOURCE SanReno

来源：SanReno